Introduction {#s1}
============

Influenza vaccination is universally recommended for individuals at increased risk for complications, but the effectiveness of current licensed vaccines has not been clearly established [@pone.0100497-Monto1], [@pone.0100497-Osterholm1]. Observational field studies have shown substantial variability in influenza vaccine effectiveness (IVE) by season, strain, and age group [@pone.0100497-Bragstad1]--[@pone.0100497-PuigBarbera1]. In addition, many of these studies are underpowered for subgroup analyses, complicating estimates of IVE for individual risks. Furthermore, differences in study design and outcome measures limit the ability to compare results across studies, and the external validity of the results is weakened when the study population does not fully represent the different vaccination settings worldwide.

Several networks have been created to provide more representative and robust estimates of IVE[@pone.0100497-Centers1]--[@pone.0100497-Valenciano1]. These networks use a more standardized approach for data collection, analysis, and reporting of IVE, but most employ passive surveillance and therefore are highly dependent on reporting timeliness and completeness [@pone.0100497-Brammer1]--[@pone.0100497-Iwane1]. Also, few networks include surveillance of severe cases requiring hospitalization.

The Global Influenza Hospital Surveillance Network (GIHSN) was launched in 2012 to address growing awareness that influenza-related hospitalization is a significant burden that remains insufficiently characterized. The GIHSN is a partnership between industry and public health institutions that uses active surveillance and a common core protocol to collect data on the epidemiology of severe influenza, as defined by hospitalization with laboratory-confirmed influenza. The principal aim of the GIHSN is to estimate, when feasible, IVE against hospitalization with influenza. Data collection in the GIHSN is coordinated by regional centers. In the GIHSN's first season (2012--2013), five coordinating centers covering 14 hospitals participated, including the *Centro Superior de Investigación en Salud Pública* (now FISABIO) (Valencia, Spain); the *Reseau National d'Investigation Clinique en Vaccinologie* (France), the Research Institute of Influenza (St. Petersburg, Russian Federation), the D.I. Ivanovsky Institute of Virology, Moscow, Russian Federation, and, as a pilot partner, the National Influenza Reference Laboratory (Cappa-Istanbul, Turkey).

Here, we used a test-negative approach [@pone.0100497-DeSerres1], [@pone.0100497-Foppa1] to estimate IVE against hospitalization with laboratory-confirmed influenza. Validity of the pooled dataset was assessed by quantifying the heterogeneity in the effect estimates across the different study sites.

Materials and Methods {#s2}
=====================

Study Design {#s2a}
------------

This was a multi-center, prospective, active surveillance, hospital-based epidemiological study carried out during the 2012--2013 Northern Hemisphere influenza season. Data were collected from14 hospitals, including five located in Valencia, Spain (Hospital General de Castellon; Hospital de la Plana; Hospital Pesset; Hospital San Juan de Alicante; Hospital General de Elda), five in France (Cochin Hospital, Paris; Bichat Hospital, Paris; Limoges Hospital; St. Eloi Hospital, Montpellier; Lyon Hospital), and four in the Russian Federation (City Infectious Diseases Hospital \#30, St. Petersburg; Children's Infectious Hospital \#5, St. Petersburg; Children's City Hospital \#4, St. Petersburg; Clinical Hospital for Infectious Diseases, Moscow). Hospitals in Turkey were not included because they were pilot partners at the time of this study. The principal objective was to estimate IVE against hospitalization with laboratory-confirmed influenza.

The protocol used by the GIHSN was approved by each site's Ethics Research Committee: *Comité Ético de la Dirección General de Salud Pública y Centro Superior de Investigación en Salud Pública* (CEIC-DGSP-CSISP); *Comité de Protection des Personnes Ile-de-France III*; Ethic Committee of Hospital \#1 for Infectious Diseases of Moscow Health Department; Ethics Committee of the Research Institute of Influenza, St. Petersburg; Istanbul University, Istanbul Faculty of Medicine, Ethical Committee for Clinical Research. All patients provided written informed consent. Briefly, data on hospitalized patients with a diagnosis possibly associated with influenza were collected by an active surveillance system composed of healthcare professionals trained to follow a generic study protocol, and influenza was confirmed by reverse transcription-polymerase chain reaction (RT-PCR). At each site, case identification was adapted to the specific local settings of the health care delivery system and type of hospital, although all sites used the same case criteria for definitive inclusion and, in all cases, the study was conducted over a period defined by the weeks with positive specimens for influenza ([Table S1](#pone.0100497.s004){ref-type="supplementary-material"}). The study was conducted according to Ethical Principles for Medical Research Involving Human Participants of the World Medical Association, the Declaration of Helsinki, and the International Ethical Guidelines for Epidemiological Studies.

Study Population {#s2b}
----------------

Non-institutionalized adults that were residents of Valencia, Spain or who held a national social security affiliation (France) and were hospitalized for at least 24 h in one of the participating hospitals were considered for inclusion in the GIHSN database. Also, patients admitted at the emergency department (Valencia, France, Russian Federation) and at certain hospital wards (France, Russian Federation) were considered if they had pre-defined chief complaints presumably associated with a previous influenza infection [@pone.0100497-PuigBarbera1]. After informed consent was obtained, patients were screened for the following inclusion criteria: onset of influenza-like-illness (ILI) within 7 days of admission to the hospital; influenza vaccination not contraindicated; not previously positive for influenza virus in the 2012--2013 season; and not hospitalized within 30 days of the current admission. ILI was defined as the presence of at least one systemic symptom (fever or feverishness, malaise, headache or myalgia) and at least one respiratory symptom (cough, sore throat or shortness of breath).

Study Conduct {#s2c}
-------------

At enrollment, a nasopharyngeal and a pharyngeal swab were collected and patients were interviewed by a hospital physician, clinical research associate, or both (Russian Federation and France) or a dedicated study nurse (Valencia). Swabs were stored at −20°C. The following data were collected during the interview or by searching clinical records: demographic characteristics; anthropometric measures; information on the ILI episode; dates of symptom onset, hospitalization, and swabbing; antiviral treatment received; intense care unit admission; death during hospitalization; main hospital admission and discharge diagnostics; presence of chronic diseases; pregnancy status; number of hospital admissions in the past 12 months; number of general practitioner consultations in the previous 3 months; smoking habits; and vaccination against influenza in the current (2012--2013) and previous (2011--2012) seasons. Physicians involved in clinical care of patients were also involved in patient recruitment but were not involved in case ascertainment.

Social class was assigned according to occupation as described previously [@pone.0100497-Galobardes1]. Functional status before ILI onset was ascertained in patients ≥65 years of age using the Barthel index [@pone.0100497-Mahoney1] and categorized as follows: total dependence, 0--15; severe dependence, 20--35; mild to moderate dependence, 40--90; no dependence, ≥95. Vaccination status during the current season was ascertained from registries, vaccination cards, and interviews with patients, their families, and their physicians. Patients were considered vaccinated if they had received at least one dose of the 2012--2013 seasonal vaccine \>14 days before the onset of ILI symptoms. Local vaccination policies and vaccines available at each coordinating site are summarized in [Table S2](#pone.0100497.s005){ref-type="supplementary-material"}.

Laboratory Confirmation of Influenza {#s2d}
------------------------------------

Commercially available (Russian Federation) or in-house (Valencia and France) RT-PCR assays were used to detect influenza A (subtypes H3 and H1) and influenza B (Yamagata and Victoria lineages) viruses in swabs ([Text S1](#pone.0100497.s009){ref-type="supplementary-material"}).

Data Management, Calculations, and Statistical Analysis {#s2e}
-------------------------------------------------------

Coordinating sites collected anonymized data and checked for missing, inconsistent, or incorrect data. Whenever possible, queries of any inconsistencies or missing data were resolved by the investigators at each of the study sites. Missing data were not replaced for the statistical analyses. Data from each coordinating site were shared with the network coordinating center (FISABIO, Valencia, Spain) through a secured web-based system.

Differences in the distribution of variables were estimated using a chi-square or T-test. A P-value of less than 0.05 was considered to indicate statistical significance.

The primary outcome measure was hospital admission with laboratory-confirmed influenza. Secondary outcome measures were hospital admissions with laboratory-confirmed influenza A(H1N1)pdm09, A(H3N2), or B/Yamagata.

IVE was determined in patients ≥18 years of age who had been swabbed within 7 days of the onset of ILI symptoms and who had been targeted for influenza vaccination because they were obese, pregnant, or ≥65 years of age, or had recorded comorbidities [@pone.0100497-Noauthors1]. In addition, patients were excluded from IVE estimates and analysis if they had received a homeopathic vaccine. IVE was estimated as (1−odds ratio\[OR\]) ×100, where the OR compared the vaccine coverage rate between influenza-positive and influenza-negative patients. Records for which outcome, exposure, or confounding variables were missing were excluded from the multivariate IVE analyses. The adjusted IVE was estimated by logistic regression using a random effects model with study site as a shared parameter for the pooled analysis and including week of symptom onset as a continuous variable, and age group, sex, hospitalization in the previous 12 months, presence of chronic conditions, and smoking habits as potential confounding factors. Parameters not normally distributed were transformed prior to analysis. Polynomial fitting was used for non-linear relationships between week of symptom onset and influenza positivity. The nonlinear relationship between the week of symptom onset (independent variable) and influenza positivity (dependent variable) was modeled as an n^th^ order polynomial, yielding the general polynomial regression model y = β~0~+β~1~x +β~2×2~ +β~3×3~+...β~n~x~n~ + Σyz~i~ + µ~i~, where the expected value of a dependent variable y (log of the odds of either influenza positivity overall, H1N1, H2N3, B/Yamagata or B/Victoria) was modeled in terms of the value of the independent variable x (week of onset), β~n~ are the coefficients, Σyz~i~ are the effects of the covariates, and µ~i~ are the random effects representing between-site variability[@pone.0100497-Motulsky1]. Sensitivity analysis was performed by including only samples taken within 4 days of symptom onset. A *P*-value \<0.05 was considered to indicate statistical significance. Heterogeneity in IVE estimates was assessed using the I^2^ statistic [@pone.0100497-Higgins1]--[@pone.0100497-Sterne1]. Potential sources of heterogeneity, including coordinating site, age, and influenza subgroup were examined in ad-hoc analyses. Heterogeneity was defined as low if I^2^ statistic \<25%, moderate if 25% to 49%, high if ≥50% as described previously[@pone.0100497-Higgins2].

Statistical analyses were performed using Stata version 13.1 (College Station, TX).

Results {#s3}
=======

Patients {#s3a}
--------

A total of 9150 patients were screened by the 14 participating hospitals ([Table 1](#pone-0100497-t001){ref-type="table"}). A total of 6581 patients met the criteria for inclusion in the GIHSN database. Of these, 2184 patients met criteria for and had available data for inclusion in the IVE analysis (896 in Valencia, 371 in France, 121 in St. Petersburg, and 670 in Moscow).

10.1371/journal.pone.0100497.t001

###### Subjects included and excluded by coordinating site.

![](pone.0100497.t001){#pone-0100497-t001-1}

                                                          Valencia   France   St Petersburg   Moscow   All                                 
  ------------------------------------------------------ ---------- -------- --------------- -------- ------ ------- ------ ------- ------ -------
  Eligible patients                                         5038     100.0         449        100.0    1986   100.0   1677   100.0   9150   100.0
  Exclusions                                                                                                                               
  Nonresident                                                63       1.3           0          0.0      0      0.0     0      0.0     63     0.7
  Institutionalized                                         329       6.5           0          0.0      7      0.4     21     1.3    357     3.9
  Unable to communicate                                     250       5.0           0          0.0      47     2.4     2      0.1    299     3.3
  Did not give consent                                      156       3.1           0          0.0     166     8.4     11     0.7    333     3.6
  Did not meet the ILI case definition                      1350      26.8          2          0.4      67     3.4     42     2.5    1461   16.0
  \>7 days between symptomonset and admission               485       9.6           2          0.4      3      0.2     63     3.8    553     6.0
  Previous hospitalization \<30 days ago                     2        0.0           0          0.0      35     1.8     19     1.1     56     0.6
  No swab taken                                              1        0.0           0          0.0      7      0.4    115     6.9    123     1.3
  Specimen collected \>7days after ILI onset                 44       0.9          12          2.7      1      0.1     4      0.2     61     0.7
  PCR result unavailableor sample inadequate                 66       1.3           4          0.9      2      0.1     8      0.5     80     0.9
  Outside of analysis period                                785       15.6          0          0.0      51     2.6     3      0.2    839     9.2
  Age \<18 years                                            396       7.9           0          0.0     1169   58.9    358    21.3    1923   21.0
  Previous influenza infection within the season             0        0.0           0          0.0      3      0.2     0      0.0     3      0.0
  Contraindication for vaccination                           0        0.0           0          0.0      9      0.5     2      0.1     11     0.1
  Influenza vaccine status unknown/missing                   0        0.0           2          0.4      4      0.2     7      0.4     13     0.1
  Homeopathic vaccine given                                  0        0.0          18          4.0      0      0.0     0      0.0     18     0.2
  Not belonging to population targeted for vaccination       89       1.8          38          8.5     294    14.8    352    21.0    773     8.4
  Included in the analysis                                  1022      20.3         371         82.6    121     6.1    670    40.0    2184   23.9

The most important reasons for exclusion from IVE analysis were not meeting the ILI case definition(n = 1461), being hospitalized outside of the analysis period (n = 839), having more than 7 days between symptom onset and hospital admission (n = 553), aged under 18 years (n = 1923) and not belonging to population targeted for vaccination (n = 773). Most of the exclusions (4016 of 4667) were in Valencia and were due to the broad selection criteria, which were designed to capture the maximum number of patients hospitalized for reasons that have been or could be associated with influenza infection.

Influenza Positives {#s3b}
-------------------

Of the 2184 patients included, 675 (30.9%) tested positive for influenza by RT-PCR ([Table 2](#pone-0100497-t002){ref-type="table"}). A(H1N1)pdm09 was the most frequently identified influenza virus (41.9%), followed by B/Yamagata (28.9%) and influenza A(H3N2) (15.1%).

10.1371/journal.pone.0100497.t002

###### RT-PCR results at each site overall and in patients 18--64 and ≥65 years of age.
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                                      RT-PCR result[a](#nt101){ref-type="table-fn"}   Influenza strain[b](#nt102){ref-type="table-fn"}                                                                                  
  ---------- ---------------- ------ ----------------------------------------------- -------------------------------------------------- ----- ------ ----- ------ ----- ------ ----- ------ ---- ----- ---- ------ ---- ------
  Overall          All         2184                       1509                                              69.1                         675   30.9   283   41.9   102   15.1   195   28.9   18   2.7   25   3.7    52   7.7
                 Valencia      992                         822                                              82.9                         170   17.1   54    31.8    5    2.9    108   63.5   2    1.2   1    0.6    0    0.0
                  France       371                         249                                              67.1                         122   32.9   24    19.7   38    31.1   49    40.2   3    2.5   8    6.6    0    0.0
              St. Petersburg   121                         39                                               32.2                         82    67.8   28    34.1   14    17.1   28    34.1   2    2.4   10   12.2   0    0.0
                  Moscow       670                         369                                              55.1                         301   44.9   177   58.8   45    15.0   10    3.3    11   3.7   6    2.0    52   17.3
  18--64 y         All         1065                        632                                              59.3                         433   40.7   229   52.9   63    14.5   60    13.9   15   3.5   20   4.6    46   10.6
                 Valencia      206                         169                                              82.0                         37    18.0   19    51.4    1    2.7    16    43.2   1    2.7   0    0.0    0    0.0
                  France       133                         85                                               63.9                         48    36.1   16    33.3   13    27.1   13    27.1   2    4.2   4    8.3    0    0.0
              St. Petersburg    93                         28                                               30.1                         65    69.9   23    35.4    8    12.3   23    35.4   1    1.5   10   15.4   0    0.0
                  Moscow       633                         350                                              55.3                         283   44.7   171   60.4   41    14.5    8    2.8    11   3.9   6    2.1    46   16.3
  ≥65 y            All         1119                        877                                              78.4                         242   21.6   54    22.3   39    16.1   135   55.8   3    1.2   5    2.1    6    2.5
                 Valencia      816                         683                                              83.7                         133   16.3   35    26.3    4    3.0    92    69.2   1    0.8   1    0.8    0    0.0
                  France       238                         164                                              68.9                         74    31.1    8    10.8   25    33.8   36    48.6   1    1.4   4    5.4    0    0.0
              St. Petersburg    28                         11                                               39.3                         17    60.7    5    29.4    6    35.3    5    29.4   1    5.9   0    0.0    0    0.0
                  Moscow        37                         19                                               51.4                         18    48.6    6    33.3    4    22.2    2    11.1   0    0.0   0    0.0    6    33.3

Percentages are compared to the total of all patients in the category.

Percentages are compared to influenza-positive patients.

### Strains isolated at each site {#s3b1}

B/Yamagata was the predominant strain isolated from patients in Valencia (63.5% of isolates), while A(H1N1)pdm09 predominated in Moscow (58.8% of isolates). In St. Petersburg, A(H1N1)pdm09 and B/Yamagata predominated and were present at similar frequencies. In France, A(H3N2) and B/Yamagata predominated ([Table 2](#pone-0100497-t002){ref-type="table"} and [Figure 1](#pone-0100497-g001){ref-type="fig"}).

![Number of admissions by epidemiological week at each site.\
The number of patients enrolled and included in the IVE analysis is shown by epidemiological week at each site for each influenza strain.](pone.0100497.g001){#pone-0100497-g001}

At each site, the distribution of strains in the patients changed as the season progressed ([Figure 1](#pone-0100497-g001){ref-type="fig"}). For example, in Valencia, B/Yamagata predominated early in the season, with a peak at epidemiological week 2013--7, whereas A(H1N1)pdm09 predominated later in the season, with a peak at epidemiological week 2013--13. In contrast, in St. Petersburg and Moscow, A(H1N1)pdm09 predominated early in the season, while B/Yamagata predominated later. The pattern in France was different than either of these countries, with several strains coexisting throughout the influenza season.

### Strains isolated by age group {#s3b2}

A(H1N1)pdm09 was more frequently isolated from patients \<65 than ≥65 years of age (52.9% vs., 22.3%, p\<0.001 by Chi^2^ test). B/Yamagata was more frequently isolated from patients ≥65 than \<65 years of age (55.8% vs. 13.9%, p\<0.001 by Chi^2^ test). A(H3N2) was evenly distributed among both age groups. B/Victoria was isolated from only 18 patients (2.7% overall) ([Table 2](#pone-0100497-t002){ref-type="table"}).

Patient Characteristics by Influenza Infection Status {#s3c}
-----------------------------------------------------

Influenza-positive patients were younger than influenza-negative patients admitted to hospital (mean age, 51 vs. 63), less likely to be men, less likely to suffer from comorbidities, and less likely to have been hospitalized in the last year but more likely to have never smoked and more likely to have professional or non-manual skilled jobs ([Table 3](#pone-0100497-t003){ref-type="table"}). Influenza-positive patients were less likely than influenza-negative patients to have been vaccinated for seasonal influenza during the 2012--2013 and 2011--2012 seasons. Of patients vaccinated for influenza during the 2012--2013 season, more influenza-negative patients had also received the 2011--2012 seasonal influenza vaccine.

10.1371/journal.pone.0100497.t003

###### Characteristics of patients included in the IVE analysis by RT-PCR result.
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                                                                                                                                                                   Influenza-negative   Influenza-positive  
  -------------------------------------------------------------------------- ------------------------------------------------------------------------------------ -------------------- -------------------- ---------
  Total                                                                                                               \-                                              1509 (69.1)           675 (30.9)         NC
  Age                                                                                                              18--49 y                                            407 (27.0)           338 (50.1)       \<0.001
                                                                                                                   50--64 y                                            225 (14.9)           95 (14.1)       
                                                                                                                   65--74 y                                            239 (15.8)           85 (12.6)       
                                                                                                                   75--84 y                                            379 (25.1)            101 (15)       
                                                                                                                    ≥85 y                                              259 (17.2)            56 (8.3)       
  Sex                                                                                                               Female                                              799 (53)            457 (67.7)       \<0.001
                                                                                                                     Male                                               710 (47)            218 (32.3)      
  Comorbidities                                                                                                       0                                                376 (24.9)            297 (44)        \<0.001
                                                                                                                      1                                                512 (33.9)           219 (32.4)      
                                                                                                                      ≥2                                               621 (41.2)           159 (23.6)      
  Obese (body massindex ≥30)                                                                                         Yes                                               427 (28.3)           163 (24.2)        0.115
  Hospitalized inthe last 12 months[a](#nt104){ref-type="table-fn"}                                                  Yes                                                480 (32)            126 (18.8)       \<0.001
  General practitionervisits last 3 months[b](#nt105){ref-type="table-fn"}                                            0                                                567 (37.6)           376 (55.7)       \<0.001
                                                                                                                      1                                                318 (21.1)           117(17.3)       
                                                                                                                      ≥2                                               575 (38.1)            155(23)        
  Smoking                                                                                                           Never                                              725 (48.1)            385 (57)        \<0.001
                                                                                                                     Past                                              525 (34.8)           168 (24.9)      
                                                                                                                   Current                                             259 (17.2)           122 (18.1)      
  Socioeconomicclass                                                                                  Professional tonon-manual-skilled                                401 (26.6)           256 (37.9)       \<0.001
                                                                                                                Manual-skilled                                         178 (11.8)            67 (9.9)       
                                                                                                              Manual-non-skilled                                       638 (42.3)           143 (21.2)      
                                                                                                                   Unknown                                             292 (19.4)            209 (31)       
  Functionalcapacity                                                          No impairment[c](#nt106){ref-type="table-fn"} ^,^ [d](#nt107){ref-type="table-fn"}       536 (61.2)           146 (60.3)       \<0.001
  Influenzavaccination[e](#nt108){ref-type="table-fn"}                                                            2012--2013                                           641 (42.5)           132 (19.6)       \<0.001
  Influenza vaccinationbased on medicalrecords only                                                               2012--2013                                           584(38.7)            112(16.6)        \<0.001
                                                                                                  2011--2012[f](#nt109){ref-type="table-fn"}                           638 (42.3)           152 (22.5)       \<0.001
  Time from onset ofsymptoms to swabbing                                                                           1 to 2 d                                            448 (29.7)           260 (38.5)       \<0.001
                                                                                                                   3 to 4 d                                            641 (42.5)           283 (41.9)      
                                                                                                                   5 to 7 d                                            420 (27.8)           132 (19.6)      

*P*-values were determined by Pearson's chi-square test. NC, not calculated.

N = 2158.

N = 2032.

N = 1069.

No impairment defined as a Barthel score \>60.

Data on vaccination were exclusively from self-reporting for only 5.2% of all vaccinated patients. None of the patients with clinical records of vaccination self-reported not having been vaccinated.

N = 2168.

The mean interval between symptom onset and specimen collection was similar for influenza-positive and influenza-negative patients (mean ± standard deviation = 3.1±1.6vs. 3.5±1.7 days), although more influenza-positive than influenza-negative patients were swabbed within 2 days. The risk of being influenza positive decreased by 3% (95% CI, 2% to 4%) (P for trend \<0.0001) for each day elapsed between symptom onset and swabbing.

Patient Characteristics by Vaccination Status {#s3d}
---------------------------------------------

Patients vaccinated during the year of the study (2012--2013) were older than unvaccinated patients (mean, 76 vs. 50 y) ([Table 4](#pone-0100497-t004){ref-type="table"}). Vaccinated patients were also more likely to be men, suffer from chronic conditions, to have been hospitalized in the last year, to have visited the general practitioner in the last 3 months, to be past smokers, and to have been influenza-vaccinated the previous year (2011--2012).

10.1371/journal.pone.0100497.t004

###### Characteristics of patients included in the IVE analysis according to vaccination the current year (2012--2013).
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                                                                                                                                                                          Notvaccinated   Vaccinated  
  --------------------------------------------------------------------------------- ------------------------------------------------------------------------------------ --------------- ------------ ---------
  Total                                                                                                                                                                    1411 (64.6)    773 (35.4)     NC
  Age group                                                                                                               18--49 y                                         713 (50.5)      32 (4.1)    \<0.001
                                                                                                                          50--64 y                                         236 (16.7)     84 (10.9)   
                                                                                                                          65--74 y                                         171 (12.1)     153 (19.8)  
                                                                                                                          75--84 y                                         185 (13.1)     295 (38.2)  
                                                                                                                           ≥85 y                                            106 (7.5)      209 (27)   
  Sex                                                                                                                      Female                                          944 (66.9)     312 (40.4)   \<0.001
                                                                                                                            Male                                           467 (33.1)     461 (59.6)  
  Comorbidities                                                                                                              0                                             605 (42.9)      68 (8.8)    \<0.001
                                                                                                                             1                                             460 (32.6)     271 (35.1)  
                                                                                                                             ≥2                                            346 (24.5)     434 (56.1)  
  Obese (body massindex ≥30)[a](#nt111){ref-type="table-fn"}                                                                Yes                                             367 (26)       223 (29)     0.244
  Hospitalized in thelast 12 months[a](#nt111){ref-type="table-fn"}                                                         Yes                                            298 (21.3)      308 (40)    \<0.001
  General practitionervisits in the last 3 months[b](#nt112){ref-type="table-fn"}                                            0                                             809 (57.3)     134 (17.3)   \<0.001
                                                                                                                             1                                             238 (16.9)     197 (25.5)  
                                                                                                                             ≥2                                            313 (22.2)      417 (54)   
  Smoking                                                                                                                  Never                                           754 (53.4)     356 (46.1)   \<0.001
                                                                                                                        Past smoker                                        372 (26.4)     321 (41.5)  
                                                                                                                       Current smoker                                      285 (20.2)     96 (12.4)   
  Socioeconomicclass                                                                                         Professional tonon-manual-skilled                             573 (40.6)     84 (10.9)    \<0.001
                                                                                                                       Manual-skilled                                      171 (12.1)      74 (9.6)   
                                                                                                                      Manual-unskilled                                     356 (25.2)      425 (55)   
                                                                                                                          Unknown                                           311 (22)      190 (24.6)  
  Functional capacity                                                                No impairment[c](#nt113){ref-type="table-fn"} ^,^ [d](#nt114){ref-type="table-fn"}    260 (56.3)     422 (64.2)   \<0.001
  Influenza vaccine                                                                             Previousseason (2011--2012)[e](#nt115){ref-type="table-fn"}                 130 (9.2)     660 (85.4)   \<0.001

*P*-values were determined by Pearson's chi-square test. NC, not calculated.

N = 2158.

N = 2032.

N = 1069.

No impairment defined as a Barthel score \>60.

N = 2168.

Patient Characteristics by Study Site {#s3e}
-------------------------------------

Patients in St. Petersburg (76.9%) and Moscow (94.5%) were mostly \<65 years of age and had either no or one chronic disease ([Table 5](#pone-0100497-t005){ref-type="table"}), regardless of influenza infection status ([Table S3](#pone.0100497.s006){ref-type="supplementary-material"}). In Moscow, 72.1% (483/670) of the patients were pregnant women (mean age, 28±5 years). The patients in France and Spain were evenly spread across age groups, and at least 70% suffered from one or more chronic condition. The pattern of chronic conditions was similar in Valencia and France (cardiovascular disease, chronic obstructive pulmonary disease, and diabetes), whereas in Moscow and St. Petersburg, the main chronic illness reported was cardiovascular disease. The median (interquartile range) number of chronic illnesses in patients with comorbidities was 1 (1--2) in Valencia, 2 (1--2) in France, 1 (1--1) in St. Petersburg, and 0 (0--1) Moscow. Influenza vaccine uptake was low in Moscow (3.3%) and St. Petersburg (0.8%) but moderate in Valencia (55.4%) and France (53.4%).

10.1371/journal.pone.0100497.t005

###### Characteristics of patients included in the IVE analysis at each site.
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                                                                                                  Valencia (N = 1022)   St. Petersburg (N = 121)   Moscow (N = 670)   France (N = 371)   Overall (N = 2184)
  ------------------------------------------------------------------------------ --------------- --------------------- -------------------------- ------------------ ------------------ --------------------
  Age group                                                                         18--49 y           66 (6.5)                37 (30.6)              578 (86.3)         64 (17.3)           745(34.1)
                                                                                    50--64 y          140 (13.7)               56 (46.3)               55 (8.2)          69 (18.6)           320 (14.7)
                                                                                    65--74 y          225 (22.0)               14 (11.6)               20(3.0)           65 (17.5)           324 (14.8)
                                                                                    75--84 y          359 (35.1)                12 (9.9)               14 (2.1)          95 (25.6)           480 (22.0)
                                                                                      ≥85 y           232 (22.7)                2 (1.7)                3 (0.5)           78 (21.0)           315 (14.4)
  Sex                                                                                 Male            559 (54.7)               52 (43.0)              121 (18.1)         196 (52.8)          928 (42.5)
                                                                                     Female           463 (45.3)               69 (57.0)              549 (81.9)         175 (47.2)         1256 (57.5)
  Comorbidities                                                                         0             135 (13.2)               27 (22.3)              465 (69.4)         46 (12.4)           673 (30.8)
                                                                                        1             378 (37.0)               67 (55.4)              159 (23.7)         127 (34.2)          731 (33.5)
                                                                                       ≥2             509 (49.8)               27 (22.3)               46 (6.9)          198 (53.4)          780 (35.7)
  Hospitalized inthe last 12 months[a](#nt116){ref-type="table-fn"}                    Yes            370 (36.2)               13 (11.9)               54 (8.1)          169 (45.6)          606(27.8)
  General practitionervisits last three months[b](#nt117){ref-type="table-fn"}          0             264 (25.8)               75 (62.0)              603 (90.0)          1 (0.3)            943 (43.2)
                                                                                        1             266 (26.0)               23 (19.0)               37 (5.5)          109 (29.4)          435 (19.9)
                                                                                       ≥2             492 (48.1)               12 (10.0)               30 (4.3)          196 (52.8)         730 (33.42)
  Smoking                                                                             Never           462 (45.2)               86 (71.1)              391 (58.4)         171 (46.1)         1110 (50.8)
                                                                                   Pastsmoker         389 (38.1)                4 (3.3)               183 (27.3)         117 (31.5)          693 (31.7)
                                                                                  Currentsmoker       171 (16.7)               31 (25.6)              96 (14.3)          83 (22.4)           381 (17.5)
  Time from onsetof symptoms toswabbing                                             1 to 2 d          230 (22.5)               36 (29.8)              337 (50.3)         105 (28.3)          708 (32.4)
                                                                                    3 to 4 d          483 (47.3)               56 (46.3)              233 (34.8)         152 (41.0)          924 (42.3)
                                                                                    5 to 7 d          309 (30.2)               29 (24.0)              100 (14.9)         114 (30.7)          552 (25.3)
  Disability[c](#nt118){ref-type="table-fn"}                                      NoImpairment         52 (63.9)                6 (21.4)                0 (0)            155 (65.1)           682 (61)
  Vaccinated forinfluenza duringthe current season (2012--2013)                        Yes            566 (55.4)                4 (3.3)                5 (0.8)           198 (53.4)          773 (35.4)

Missing: St. Petersburg, n = 12; France, n = 1.

Missing: St. Petersburg, n = 11; France, n = 65.

Presented only for patients ≥65 years of age. No impairment defined as a Barthel score \>60. Data missing: St. Petersburg, n = 13; Moscow, n = 37.

IVE {#s3f}
---

### Overall {#s3f1}

Influenza-positive patients were less likely to have been vaccinated during the year of the study (2012--2013) than influenza-negative patients (adjusted OR = 0.67 \[95% CI, 0.51 to 0.89\]; P = 0.0060). This corresponded to an overall adjusted IVE of 33% (95% CI, 11% to 49%) ([Table 6](#pone-0100497-t006){ref-type="table"}). IVE was similar in patients \<65 and ≥65 years of age (35% \[95% CI, −15% to 63%\] vs. 31% \[95% CI, 4% to 51%\]). When pregnant women were excluded, values were similar (IVE \[95% CI\] = 33% \[10% to 49%\] overall, 15% \[−23% to 54%\] for A(H1N1), 33% \[−32% to 66%\]for A(H3N2), and 42%\[16% to 60%\]for B/Yamagata; data not shown). IVE estimates in subjects ≥65 years of age were similar when adjusted for disability (i.e. Barthel score as a categorical variable) (data not shown).

10.1371/journal.pone.0100497.t006

###### Pooled IVE in hospitalized patients swabbed within 7 days of symptom onset.
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                            Influenzapositive   Influenzanegative   IVE adjusted forsite[a](#nt120){ref-type="table-fn"}   Fully adjustedIVE[a](#nt120){ref-type="table-fn"} ^,^ [b](#nt121){ref-type="table-fn"}                                                 
  -------------- --------- ------------------- ------------------- ------------------------------------------------------ ---------------------------------------------------------------------------------------- ------ ----- ----- ------- ----- ----- ------- -----
  Allinfluenza    Overall          132                 675                                  20%                                                                     641                                             1509   42%   44%    27%    57%   33%    11%    49%
                  \<65 y           21                  433                                   5%                                                                      95                                             632    15%   51%    15%    72%   35%   −15%    63%
                   ≥65 y           111                 242                                  46%                                                                     546                                             877    62%   43%    22%    58%   31%    4%     51%
  A(H1N1)         Overall          33                  286                                  12%                                                                     641                                             1509   42%   52%    25%    70%   23%   −26%    53%
                  \<65 y            8                  232                                   3%                                                                      95                                             632    15%   59%    7%     82%   40%   −43%    75%
                   ≥65 y           25                  54                                   46%                                                                     546                                             877    62%   34%   −22%    64%   13%   −68%    55%
  A(H3N2)         Overall          22                  102                                  22%                                                                     641                                             1509   42%   33%   −23%    64%   30%   −37%    64%
                  \<65 y            5                  63                                    8%                                                                      95                                             632    15%   18%   −147%   73%   19%   −162%   75%
                   ≥65 y           17                  39                                   44%                                                                     546                                             877    62%   46%   −16%    75%   39%   −40%    73%
  B/Yamagata      Overall          70                  195                                  36%                                                                     641                                             1509   42%   43%    20%    59%   43%    17%    60%
                  \<65 y            6                  60                                   10%                                                                      95                                             632    15%   58%    −5%    83%   52%   −25%    81%
                   ≥65 y           64                  135                                  47%                                                                     546                                             877    62%   46%    23%    63%   41%    12%    61%

CI, confidence interval; IVE, influenza vaccine effectiveness.

Site as a random effect.

Adjusted by week of symptom onset, age group, sex, hospitalization in the previous 12 months, presence of chronic conditions, and smoking habits.

### By strain {#s3f2}

IVE estimates were 23% (95% CI, −26% to 53%) for influenza A(H1N1)pdm09, 30% (95% CI, −37% to 64%) for influenza A(H3N2), and 43% (95% CI, 17% to 60%) for influenza B/Yamagata([Table 6](#pone-0100497-t006){ref-type="table"}). IVE was higher in patients \<65 years of age than in those ≥65 years of age for A(H1N1)pdm09 (40% \[95% CI, −43% to 75%\] vs. 13% \[−68% to 55%\]) and B/Yamagata (52% \[95% CI, −25% to 81%\] vs. 41% \[95% CI, 12% to 61%\]). Results were similar when the analyses were restricted to patients swabbed within 4 days of symptom onset ([Table S4](#pone.0100497.s007){ref-type="supplementary-material"}). Significant adjusted IVE estimates were obtained for all influenza in subjects ≥65 years of age and the B/Yamagata lineage, also in subjects ≥65 years of age. Analysis of the influence of socioeconomic factors was not possible due to a high proportion of "don't know" responses (data not shown).

Heterogeneity in IVE Estimates {#s3g}
------------------------------

Heterogeneity between sites was low for overall IVE estimates (I^2^ = 7.6%; *P* = 0.362) ([Figure 2](#pone-0100497-g002){ref-type="fig"}). Heterogeneity between sites was also low for IVE estimates in patients \<65 years of age (I^2^ = 7.6%; *P* = 0.362) but moderate in patients ≥65 years of age (I^2^ = 32.7%; *P* = 0.179) ([Figure 3](#pone-0100497-g003){ref-type="fig"}). Heterogeneity across sites in IVE estimates was moderate for A(H1N1)pdm09 (I^2^ = 31.6%; *P* = 0.198), whereas IVE estimates for each site were homogenous for A(H3N2) (I^2^ = 0.0%, *P* = 0.969) and B/Yamagata (I^2^ = 0.0%; *P* = 0.588, respectively) ([Figure 4](#pone-0100497-g004){ref-type="fig"}).

![Heterogeneity of IVE estimates at each site overall.](pone.0100497.g002){#pone-0100497-g002}

![Heterogeneity of IVE estimates at each site for each age group.](pone.0100497.g003){#pone-0100497-g003}

![Heterogeneity of IVE estimates at each site for each strain.](pone.0100497.g004){#pone-0100497-g004}

IVE estimates against H3N2 or B/Yamagata were also homogenous when assessed by age group, strain, and study site (I^2^ = 0.0%; *P*\>0.8) ([Figures 5](#pone-0100497-g005){ref-type="fig"} and [6](#pone-0100497-g006){ref-type="fig"}). Heterogeneity in IVE estimates was high (I^2^ = 78%; *P* = 0.0340) for A(H1N1)pdm09 in patients ≥65 years of age, with poorer protection in Valencia than in France.

![Heterogeneity of IVE estimates for each strain in patients 18--64 years of age.](pone.0100497.g005){#pone-0100497-g005}

![Heterogeneity of IVE estimates for each strain in patients ≥65 years of age.](pone.0100497.g006){#pone-0100497-g006}

All heterogeneity results were similar when assessed using adjusted IVE estimates ([Figures S1](#pone.0100497.s001){ref-type="supplementary-material"}, [S2](#pone.0100497.s002){ref-type="supplementary-material"}, and [S3](#pone.0100497.s003){ref-type="supplementary-material"}).

Discussion {#s4}
==========

This study, performed in three different countries during the 2012--2013 influenza season, used a test-negative design to estimate IVE against hospitalization with laboratory-confirmed influenza in adults targeted for vaccination. All patients included in the IVE estimates and analysis had to have been tested for influenza within 7 days of the onset of ILI symptoms. The pooled adjusted IVE was 33% (95% CI, 11% to 49%) against hospitalization. Estimates of IVE for preventing hospital admissions were consistent and moderate across sites and age groups for influenza B/Yamagata (43% \[95% CI, 17% to 60%\]) but low and non-significant for influenza A(H1N1)pdm09 (30% \[95% CI, −37% to 64%\]) and A(H3N2) (23% \[95% CI, −26% to 53%\]). IVE estimates for A(H1N1)pdm09 were highly heterogeneous across study sites in patients ≥65 years of age but not in younger patients. Influenza A(H1N1)pdm09 and B/Yamagata followed by A(H3N2) were the most common strains isolated. These results agree with other interim and preliminary results published for the 2012--2013 influenza season [@pone.0100497-Bragstad1], [@pone.0100497-McMenamin1], [@pone.0100497-Noauthors2]--[@pone.0100497-Valenciano2].

The low IVE estimates in this study might have been due to genetic drift in influenza at key antigenic sites[@pone.0100497-McMenamin1]. Genetic and possible antigenic mismatches have been described in Europe for A(H1N1)pdm09 and A(H3N2)[@pone.0100497-Sterne1]--[@pone.0100497-Noauthors3]. Vaccines for the 2012--2013 season containing A/Victoria/361/2011 antigens have been reported to induce antibodies in humans that bind less effectively to most cell-propagated influenza A(H3N2), apparently due to antigenic changes in earlier A/Victoria/361/2011-like vaccine viruses associated with adaptation of the virus to propagation in eggs[@pone.0100497-World1]. Accordingly, vaccines for the 2013--2014 northern hemisphere season are recommended to contain A(H3N2) virus that is antigenically like the cell-propagated prototype virus A/Victoria/361/2011[@pone.0100497-World1]. In contrast, in two preliminary analyses of North American data, IVE was moderate and significant against A(H3N2), although this was associated with a good antigenic match between circulating and vaccine A(H3N2) strains [@pone.0100497-Centers1], [@pone.0100497-Skowronski2].

The IVE estimates in this study were similar to those reported in sentinel hospital-based studies [@pone.0100497-Cheng1], [@pone.0100497-Cheng2] but were lower than reported for general practitioner-attended influenza outcomes[@pone.0100497-Castilla1], [@pone.0100497-Valenciano2]. This might be because of different effectiveness for different clinical outcomes or because of the generally older age and poorer health of patients requiring hospital admission for influenza infections. Indeed, our study patients were, on average, older and in poorer health than those in the general practitioner sentinel studies. Also, in contrast to some of these general practitioner sentinel studies, our estimates of IVE against influenza A strains were similar across age groups. However, in all reports, including ours, IVE against B/Yamagata influenza was moderate, despite differences in baseline patient characteristics.

The validity of IVE estimates can be influenced by nonspecific case definition, ascertainment, information bias and confounding. To overcome some of these limitations, we used a hospital-based active-surveillance approach to identify eligible patients. Despite each site adapting screening criteria to the particular circumstances of their health care systems and the participating hospitals, all sites consistently applied the network eligibility criteria. In addition, to reduce bias, at all sites, subjects were screened and included in the study without previous knowledge of their exposure or outcome status and belonged to the same population at risk for influenza infection, namely, those targeted for vaccination[@pone.0100497-Rothman1]. All sites used the common GIHSN core protocol and close follow-up and feedback between the coordination center and the different sites to ensure that standard procedures and monitoring were employed throughout the influenza season.

We used a highly specific outcome definition of severe influenza, with influenza infection confirmed by RT-PCR performed in highly qualified central laboratories. To minimize the impact of false negatives on IVE estimates, we excluded patients swabbed more than 7 days after the onset of symptoms [@pone.0100497-Rothman1]. IVE was estimated using the widely used test-negative approach, which has been shown to give consistent results[@pone.0100497-DeSerres1], and the analysis of IVE was restricted to periods with similar influenza circulation patterns[@pone.0100497-Foppa1], [@pone.0100497-Sullivan1]. Furthermore, the IVE was calculated on the basis of ORs determined using a random effects model, which allowed us to take into account potential differences, including type of vaccine, vaccination programs, the levels of immunity across different population and settings, and different use of hospital emergency departments [@pone.0100497-Kirkwood1], [@pone.0100497-PuigBarbera2].

Underlying heterogeneity across study sites may have compromised the accuracy of the overall IVE estimates. We observed high heterogeneity in the estimates of IVE against A(H1N1)pdm09 by site in patients ≥65 years of age. This was mainly due to opposing directions of IVE estimates in France and Valencia. Identifying the host and pathogen factors that may have contributed to this variability is complicated by limited understanding of the factors that affect annual IVE estimates [@pone.0100497-Smith1]. One possibility for the heterogeneity is site-specific genetic and antigenic differences between circulating A(H1N1)pdm09 and seasonal vaccine viruses[@pone.0100497-Noauthors3], [@pone.0100497-Anton1], [@pone.0100497-Daniels1]. We cannot exclude the possibility that the differences between sites are due, at least to some extent, to different vaccines being used.

The heterogeneity of pooled analyses from existing influenza networks and the relevance of IVE estimates across sites sharing a core standardized protocol remain largely unknown [@pone.0100497-Talbot1], [@pone.0100497-Treanor1]. A thorough assessment and exploration of the heterogeneity inherent to multicenter studies is needed to evaluate the robustness of pooled IVE results and the identification of risk factors. One possible framework for understanding the heterogeneity of observational IVE data and how to interpret it is that provided by Beyer et al. who re-analyzed data from a 2010 Cochrane meta-analysis of IVE in the elderly[@pone.0100497-Beyer1]. By rearranging the data according to "a biological and conceptual framework based on the basic sequence of events throughout the 'patient journey'", they found a mean IVE against complications of 28% (95% CI, 26% to 30%) and against laboratory-confirmed disease of 49% (95% CI, 33% to 62%). They concluded that their findings provide "substantial evidence for the ability of influenza vaccine to reduce the risk of influenza infection and influenza-related disease and death in the elderly." Although both their and our analyses were based on heterogeneous source data, we had similar findings and reached similar conclusions on the effectiveness of influenza vaccines.

The wide confidence intervals observed in our study suggests that small sample sizes may have compromised the precision around risk-specific IVE estimates and the power of statistical tests to detect all sources of heterogeneity. Therefore, random error could have affected our estimates. Accordingly, the IVE estimates should be interpreted with caution. The results of this study support the feasibility of estimating IVE against hospitalization for laboratory-confirmed influenza based on a global active-surveillance hospital-based network. New sites in China and Brazil, and a fully operational site in Turkey will be joining the GIHSN in the 2013--2014 season. This will increase its geographical representativeness and sample size, which will improve the validity and accuracy of data on influenza vaccine effects and their variability. This is especially important for attaining the principal public health objectives of preventing morbidity and premature mortality in people at high risk for complications from influenza.
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